1 Drug Store Stock to Purchase Over Walgreens

NYSE: CVS | CVS Health Corporation  News, Ratings, and Charts

CVS – Drug store stock CVS Health (CVS) outperformed Walgreens (WBA) over the past year. Moreover, Wall Street analysts expect CVS to see a better upside than WBA in the upcoming months because of its stronger fundamentals. So, it appears to be a better buy now. Keep reading….

Health services provider CVS Health Corporation (CVS) has lost 9.9% over the past month amid the broader market sell-off. However, the healthcare sector’s resilience to uncertain economic conditions and the company’s solid fundamentals have helped the stock deliver 8.8% returns over the past year.

On the other hand, pharmacy retailer Walgreens Boots Alliance, Inc. (WBA) could not survive the challenges faced by the market well and lost 31.6% over the past year. The company’s poor fundamentals are the key reason behind its underperformance.

WBA’s sales came in at $32.45 billion for the quarter ended August 31, 2022, down 5.3% year-over-year. Its net loss came in at $415 million compared to an income of $627 million a year ago. Its loss per share came in at $0.48 compared to an EPS of $0.72 in the year-ago period.

Given CVS’ fundamental strength, Wall Street analysts expect the stock to hit $122.31 in the near term, indicating a potential upside of 33%, which is much higher than what WBA could see.

Here is what could shape CVS’ performance in the near term:

Solid Financials

CVS’ total revenues increased 11% year-over-year to $80.64 billion for the second quarter ended June 30, 2022. Its net income came in at $2.95 billion, up 6% year-over-year, while its EPS came in at $2.23, up 6.2% year-over-year. Moreover, its operating income came in at $4.57 billion, up 5.6% year-over-year.

Attractive Valuations

CVS’ forward EV/Sales of 0.57x is 84.9% lower than the industry average of 3.80x. Its forward EV/EBITDA of 8.94x is 31% lower than the industry average of 12.94x. Also, its forward Price/Sales of 0.39x is 91.2% lower than the industry average of 4.38x, while its forward Price/Book of 1.51x is 40.2% lower than the industry average of 2.53x.

Robust Profitability Margins

CVS’ trailing-12-month EBITDA margin of 6.14% is 86.4% higher than the industry average of 3.29%. Its trailing-12-month net income margin of 2.66% is higher than the negative industrial average of 2.69%.

In addition, its trailing-12-month ROCE, ROTC, and ROTA of 11.00%, 5.96%, and 3.55%, compared with the industry averages of negative 38.60%, 21.31%, and 29.63%, respectively.

POWR Ratings Reflect Promising Outlook

CVS has an overall rating of A, which equates to a Strong Buy in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

The stock has a B grade for Growth, consistent with its solid financials in the latest reported quarter. It has a B grade for Stability, in sync with its beta of 0.71.

In the 4-stock Medical – Drug Stores industry, CVS is ranked first.

Click here for the additional POWR Ratings for CVS (Value, Momentum, Sentiment, Quality).

View all the top stocks in the Medical – Drug Stores industry here.

Bottom Line

While WBA delivered a poor performance in the last reported quarter, CVS’ financials have witnessed stable growth. Moreover, CVS’ revenue is expected to increase 6.9% year-over-year to $312.35 billion in 2022. Its EPS is estimated to grow 6.2% per annum for the next five years.

Given the stock’s sturdy financials and robust profitability, I think CVS could be a better Buy than WBA.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


CVS shares were unchanged in after-hours trading Wednesday. Year-to-date, CVS has declined -9.69%, versus a -21.52% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CVSGet RatingGet RatingGet Rating
WBAGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Does Trump Change Stock Market Outlook?

The rally of the S&P 500 (SPY) after the election gives a sense that investors are happy that Trump was elected. But perhaps there is more to this story than meets the eye. That’s why Steve Reitmeister shares his updated market outlook taking into account the pros and cons of Trumps proposed new policies. This comes with a preview of his top 11 stocks to buy now.

3 Streaming Stocks Benefiting from Cord-Cutting Trends

As streaming continues to dominate the digital entertainment landscape, the global streaming market presents a lucrative investment opportunity. So, it could be ideal to invest in fundamentally solid streaming stocks Netflix (NFLX), Walt Disney (DIS), and Roku (ROKU). Read further...

3 Gold Stocks to Buy as Safe-Haven Demand Grows

Gold is a stable investment now due to its role as a safe-haven asset during economic uncertainty, rising demand, industrial use, and growth, bolstered by central bank purchases and interest rate cuts. Therefore, investors should consider investing in top gold stocks such as Newmont (NEM), Barrick Gold (GOLD), and Agnico Eagle Mines (AEM). Read more...

3 AI Stocks Transforming Industries and Driving Future Growth

With rapid digitalization, rapid adoption, and development, as well as surging demand, the AI market is on the rise. Amid this backdrop, investors could buy fundamentally solid AI stocks NVIDIA Corporation (NVDA), Microsoft (MSFT), and Meta Platforms (META) poised for substantial gains. Continue reading...

Updated Stock Market Expectations

The S&P 500 (SPY) has already reached an impressive goal of hitting 6,000. Yet you can see how much shares are struggling now up against this resistance. Steve Reitmeister shares his views on what comes next for the market and his top 10 stocks to stay on the right side of the action.

Read More Stories

More CVS Health Corporation (CVS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CVS News